pharmaphorum

Roche puts pressure on SMA rivals with new FDA approval

Roche and PTC Therapeutics' Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than two months ...
pharmaphorum

Roche takes on pricey rivals as FDA approves SMA drug

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is the third treatment approved for SMA, an ...
Investopedia

Separate Accounts Explained: How They Work and Key Benefits

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...
Indiatimes

SMA-50 Crossed Above SMA-20

SMA-50 Crossed Above SMA-20 Stocks- 50 day moving avergae above 20 day moving average: The primary application of Simple Moving Average is for analyzing stock trends Multiply the power of your ...